华蟾素联合经肝动脉化疗栓塞治疗原发性肝细胞癌的临床效果作者：贾金莹来源：《中国当代医药》2016年第08期
[摘要] 目的 探讨华蟾素联合经肝动脉化疗栓塞（TACE）治疗原发性肝细胞癌（HCC）的临床效果。 方法 选取本院2010年1月～2012年6月收治的95例原发性HCC患者作为研究对象，随机分为联合组和对照组。联合组采用TACE+华蟾素治疗，对照组采用单纯TACE治疗。比较两组的近期疗效、SF-36量表评分和T淋巴细胞功能水平。 结果 联合组的总缓解率为44.90%，显著高于对照组的34.78%，差异有统计学意义（P
[关键词] 原发性肝细胞癌；经导管肝动脉栓塞术；介入治疗；生活质量；细胞免疫
[中图分类号] R735.7 [文献标识码] A [文章编号] 1674-4721（2016）03（b）-0052-04
[Abstract] Objective To explore the clinical effect of cinobufagin combined with transhepatic arterial chemotherapy and embolization （TACE） in the treatment of primary hepatocellular carcinoma （HCC）. Methods 95 patients with primary HCC from January 2010 to June 2012 in our hospital were selected and randomly divided into the combination group and the control group.The combination group was treated with cinobufagin conbined with TACE，the control group was treated with TACE.The short-term efficacy，SF-36 scale score and the level of T lymphocyte function in the two groups was compared. Results The total remission rate in the combination group was 44.90%，which was higher than 34.78% in the control group，with significant difference （P
本文来源：https://www.2haoxitong.net/k/doc/68f540193a3567ec102de2bd960590c69fc3d854.html
文档为doc格式